MicroRNA‑133a inhibits the proliferation of non‑small cell lung cancer by targeting YES1

Shen,Yuyao; Chen,Fangwei; Liang,Yanchao

doi:10.3892/ol.2019.11030

MicroRNA‑133a inhibits the proliferation of non‑small cell lung cancer by targeting YES1

Authors:
- Yuyao Shen
- Fangwei Chen
- Yanchao Liang
View Affiliations

Affiliations: Department of Respiratory Medicine, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong 264000, P.R. China, Department of Respiratory Medicine, The Affiliated Zhuzhou Hospital of Xiangya Medical College CSU, Zhuzhou, Hunan 412000, P.R. China
Published online on: November 1, 2019 https://doi.org/10.3892/ol.2019.11030
Pages: 6759-6765
Copyright: © Shen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Previous studies have reported that microRNA‑133a (miR‑133a) is involved in the pathogenesis of human cancers. This study investigated the effect of miR‑133a on cell proliferation in non‑small cell lung cancer (NSCLC). The expression of miR‑133a and YES proto‑oncogene 1 (YES1) was detected using reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR) assay. The CCK‑8 assay was used to measure cell proliferation. The relationship between miR‑133a and YES1 was confirmed by dual luciferase assay. Downregulation of miR‑133a was identified in NSCLC and correlated with poor prognosis in NSCLC patients. Moreover, the overexpression of miR‑133a inhibited proliferation of NSCLC cells. YES1 was also confirmed as a direct target of miR‑133a. Downregulation of YES1 was found to inhibit cell proliferation in NSCLC. By contrast, the upregulation of YES1 abolished the inhibitory effect of miR‑133a on cell proliferation in NSCLC. miR‑133a inhibited cell proliferation in NSCLC by targeting YES1, indicating that miR‑133a can be used as an indicator of prognosis in NSCLC patients.

View Figures

View References

1	Ramalingam SS, Owonikoko TK and Khuri FR: Lung cancer: New biological insights and recent therapeutic advances. CA Cancer J Clin. 61:91–112. 2011. View Article : Google Scholar : PubMed/NCBI
2	Sharma A, O'Connor R, Celestino P, Killion S, Griswold-Krupski L and Bansal-Travers M: Focus groups and in-depth interviews to guide the development of lung cancer screening informational materials. J Cancer Educ. Apr 20–2018.(Epub ahead of print). doi: 10.1007/s13187-018-1362-4.
3	Pao W and Girard N: New driver mutations in non-small-cell lung cancer. Lancet Oncol. 12:175–180. 2011. View Article : Google Scholar : PubMed/NCBI
4	Tang Z, Li J, Shen Q, Feng J, Liu H, Wang W, Xu L, Shi G, Ye X, Ge M, et al: Contribution of upregulated dipeptidyl peptidase 9 (DPP9) in promoting tumorigenicity, metastasis and the prediction of poor prognosis in non-small cell lung cancer (NSCLC). Int J Cancer. 140:1620–1632. 2017. View Article : Google Scholar : PubMed/NCBI
5	Yang F, Wei K, Qin Z, Liu W, Shao C, Wang C, Ma L, Xie M, Shu Y and Shen H: miR-598 suppresses invasion and migration by negative regulation of Derlin-1 and epithelial-mesenchymal transition in non-small cell lung cancer. Cell Physiol Biochem. 47:245–256. 2018. View Article : Google Scholar : PubMed/NCBI
6	Yang JZ, Bian L, Hou JG and Wang HY: miR-550a-3p promotes non-small cell lung cancer cell proliferation and metastasis through down-regulating TIMP2. Eur Rev Med Pharmacol Sci. 22:4156–4165. 2018.PubMed/NCBI
7	Huang Y, Wu Y, Dong J, Han D, Yang S and Jiang L: MicroRNA-133a-3p exerts inhibitory effects on gallbladder carcinoma via targeting RBPJ. Am J Cancer Res. 6:2448–2462. 2016.PubMed/NCBI
8	Gao SH, Liu J, Zhang HJ, Zhao N and Zhang J: Low miR-133a expression is a predictor of outcome in patients with esophageal squamous cell cancer. Eur Rev Med Pharmacol Sci. 20:3788–3792. 2016.PubMed/NCBI
9	Wang Y, Li J, Chen H, Mo Y, Ye H, Luo Y, Guo K, Mai Z, Zhang Y, Chen B, et al: Down-regulation of miR-133a as a poor prognosticator in non-small cell lung cancer. Gene. 591:333–337. 2016. View Article : Google Scholar : PubMed/NCBI
10	Cai J, Liu T, Huang P, Yan W, Guo C, Xiong L and Liu A: USP39, a direct target of microRNA-133a, promotes progression of pancreatic cancer via the AKT pathway. Biochem Biophys Res Commun. 486:184–190. 2017. View Article : Google Scholar : PubMed/NCBI
11	Yeung CL, Ngo VN, Grohar PJ, Arnaldez FI, Asante A, Wan X, Khan J, Hewitt SM, Khanna C, Staudt LM, et al: Loss-of-function screen in rhabdomyosarcoma identifies CRKL-YES as a critical signal for tumor growth. Oncogene. 32:5429–5438. 2013. View Article : Google Scholar : PubMed/NCBI
12	Je DW, O YM, Ji YG, Cho Y and Lee DH: The inhibition of SRC family kinase suppresses pancreatic cancer cell proliferation, migration, and invasion. Pancreas. 43:768–776. 2014. View Article : Google Scholar : PubMed/NCBI
13	Sato A, Sekine M, Virgona N, Ota M and Yano T: Yes is a central mediator of cell growth in malignant mesothelioma cells. Oncol Rep. 28:1889–1893. 2012. View Article : Google Scholar : PubMed/NCBI
14	Iida M, Brand TM, Campbell DA, Li C and Wheeler DL: Yes and Lyn play a role in nuclear translocation of the epidermal growth factor receptor. Oncogene. 32:759–767. 2013. View Article : Google Scholar : PubMed/NCBI
15	Seki T, Fujii G, Mori S, Tamaoki N and Shibuya M: Amplification of c-yes-1 proto-oncogene in a primary human gastric cancer. Jpn J Cancer Res. 76:907–910. 1985.PubMed/NCBI
16	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
17	Wang B, Sun L, Li J and Jiang R: miR-577 suppresses cell proliferation and epithelial-mesenchymal transition by regulating the WNT2B mediated Wnt/β-catenin pathway in non-small cell lung cancer. Mol Med Rep. 18:2753–2761. 2018.PubMed/NCBI
18	Han L, Chen W, Xia Y, Song Y, Zhao Z, Cheng H and Jiang T: miR-101 inhibits the proliferation and metastasis of lung cancer by targeting zinc finger E-box binding homeobox 1. Am J Transl Res. 10:1172–1183. 2018.PubMed/NCBI
19	Sui Y, Zhang X, Yang H, Wei W and Wang M: MicroRNA-133a acts as a tumour suppressor in breast cancer through targeting LASP1. Oncol Rep. 39:473–482. 2018.PubMed/NCBI
20	Li W, Chen A, Xiong L, Chen T, Tao F, Lu Y, He Q, Zhao L, Ou R and Xu Y: miR-133a acts as a tumor suppressor in colorectal cancer by targeting eIF4A1. Tumour Biol. 39:10104283176983892017.PubMed/NCBI
21	Sun L, Guo Z, Sun J, Li J, Dong Z, Chen J, Kan Q and Yu Z: miR-133a acts as an anti-oncogene in hepatocellular carcinoma by inhibiting FOSL2 through TGF-beta/Smad3 signaling pathway. Biomed Pharmacother. 107:168–176. 2018. View Article : Google Scholar : PubMed/NCBI
22	Li C, Li X, Gao S, Li C and Ma L: MicroRNA-133a inhibits proliferation of gastric cancer cells by downregulating ERBB2 expression. Oncol Res. 25:1169–1176. 2017. View Article : Google Scholar : PubMed/NCBI
23	Li H, Wang Y and Li YZ: MicroRNA-133a suppresses the proliferation, migration, and invasion of laryngeal carcinoma cells by targeting CD47. Tumour Biol. 37:16103–16113. 2016. View Article : Google Scholar
24	Farazi TA, Juranek SA and Tuschl T: The growing catalog of small RNAs and their association with distinct Argonaute/Piwi family members. Development. 135:1201–1214. 2008. View Article : Google Scholar : PubMed/NCBI
25	Zhou GQ, Han F, Shi ZL, Yu L, Li XF, Yu C, Shen CL, Wan DW, Zhu XG, Li R, et al: miR-133a-3p targets SUMO-specific protease 1 to inhibit cell proliferation and cell cycle progress in colorectal cancer. Oncol Res. 26:795–800. 2018. View Article : Google Scholar : PubMed/NCBI
26	Dong X, Su H, Jiang F, Li H, Shi G and Fan L: miR-133a, directly targeted USP39, suppresses cell proliferation and predicts prognosis of gastric cancer. Oncol Lett. 15:8311–8318. 2018.PubMed/NCBI
27	Garmendia I, Pajares MJ, Hermida-Prado F, Ajona D, Bértolo C, Sainz C, Lavín A, Remírez AB, Valencia K, Moreno H, et al: YES1 drives lung cancer growth and progression and predicts sensitivity to dasatinib. Am J Respir Crit Care Med. Jun 5–2019.(Epub ahead of print). doi: 10.1164/rccm.201807-1292OC. View Article : Google Scholar : PubMed/NCBI
28	Fang Z, Yin S, Sun R, Zhang S, Fu M, Wu Y, Zhang T, Khaliq J and Li Y: miR-140-5p suppresses the proliferation, migration and invasion of gastric cancer by regulating YES1. Mol Cancer. 16:1392017. View Article : Google Scholar : PubMed/NCBI